2025 PRIMO | Major Endocrine and Targeted Therapy Advances In the Treatment of HR+/HER2- Breast Cancer
Overview
NA
Target Audience
NA
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Vicente Valero, MD, FACP
Date of Release
May 14th, 2025
-1750785566843.webp&w=3840&q=75)
